BioXcel Therapeutics Inc. will host a virtual key opinion leader $(KOL)$ roundtable on the latest developments in treating acute agitation in Alzheimer’s dementia on Friday, February 27, from 2:00 to 3:00 p.m. EST, featuring medical experts discussing unmet needs and the potential role of its late-stage candidate BXCL501. Registration is available here: https://www.globenewswire.com/Tracker?data=GAoD1zAIZ5rgf3foWv1IqqwGyqWXP3lrKjlaXiYOhZwrAlU6RVgYBalehMDqfpVHnzoUq84iNg1PHmfwUDkGlFeti2NjYgG9zT188CAyKsx8Zrw-kt3IiI2veHCkguN8Jtj1EO2bqLQU8uObVzWzEw==. Additional event-related links in the announcement include moderator details (Anjalee Khemlani): https://www.globenewswire.com/Tracker?data=9q_qaLJj5zKEE_LifBUCEx4HsIJgAjrfkOtH62FcalvFZ6GYxgTyBtJE5vjy4wztK0UQenhHUqUI3guAq6K5QYmu5YwjkjQ-ZURpcav-n70=, and panelist profiles: George T. Grossberg, MD (https://www.urmc.rochester.edu/people/112358668-anton-p-porsteinsson), Anton P. Porsteinsson, MD (https://www.urmc.rochester.edu/people/112358668-anton-p-porsteinsson), and Angela Sanford, MD (https://www.getcare.ssmhealth.com/find-a-doctor/doctor-details/angela-sanford-md).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602190700PRIMZONEFULLFEED9657251) on February 19, 2026, and is solely responsible for the information contained therein.